An update on treatment and prevention strategies for Alzheimer's disease

Current Neurology and Neuroscience Reports

Volumn 9, Issue 5, 2009, Pages 368-376

  Neugroschl, Judith ^a   Sano, Mary ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR INHIBITOR; ALZHEIMER DISEASE VACCINE; ANTIINFLAMMATORY AGENT; ATORVASTATIN; BAPINEUZUMAB; CAD 106; CONJUGATED ESTROGEN; DIMEBON; DOCOSAHEXAENOIC ACID; ENZYME MODULATOR; GINKGO BILOBA EXTRACT; HOMOCYSTEINE; HOMOTAURINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; METHYLENE BLUE; N2 [2 (3,5 DIFLUOROPHENYL) 2 HYDROXYACETYL] N1 (6,7 DIHYDRO 5 METHYL 6 OXO 5H DIBENZ[B,D]AZEPIN 7 YL)ALANINAMIDE; PF 04494700; PLACEBO; PROGESTERONE; PRX 03140; QS 21; REMBER; SEROTONIN 4 RECEPTOR; SIMVASTATIN; TARENFLURBIL; TRX 0014; UNCLASSIFIED DRUG; VITAMIN B GROUP;

ACTIVE IMMUNIZATION; ADJUVANT THERAPY; AGING; ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; AMINO TERMINAL SEQUENCE; APOPTOSIS; CLINICAL TRIAL; COGNITION; DEMENTIA; DIARRHEA; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; GASTROINTESTINAL HEMORRHAGE; HOMOCYSTEINE BLOOD LEVEL; HUMAN; HUMORAL IMMUNITY; LOW DRUG DOSE; MENINGOENCEPHALITIS; MICROTUBULE ASSEMBLY; NEUROFIBRILLARY TANGLE; NONHUMAN; PASSIVE IMMUNIZATION; PATHOGENESIS; PHYSICAL ACTIVITY; PROTEIN BINDING; PROTEIN BLOOD LEVEL; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; REVIEW; T LYMPHOCYTE ACTIVATION; TRAINING; VACCINATION; VASOGENIC EDEMA; VITAMIN SUPPLEMENTATION;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; HUMANS; IMMUNOTHERAPY;

EID: 68449087508     PISSN: 15284042     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11910-009-0054-1     Document Type: Review

References (72)

1. Barten DM, Albright CF: Therapeutic strategies for Alzheimer's disease. Mol Neurobiol 2008, 37:171-186.
2. Nicoll JA, Wilkinson D, Holmes C, et al.: Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: A case report. Nat Med 2003, 9:448-452.
3. Gilman S, Koller M, Black RS, et al.: Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology 2005, 64:1553-1562.
4. Elan: Elan and Wyeth to Initiate Phase 3 Clinical Trial of Bapineuzumab (AAB-001) in Alzheimer's Disease. Available at http://www.elan.com/news/ 2007/20070521.asp. Accessed June 23, 2009.
5. Wyeth: Elan and Wyeth Announce Encouraging Top-Line Results from Phase 2 Clinical Trial of Bapineuzumab for Alzheimer's Disease. Available at http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/home/news/ pressreleases/2008/1213683456273.html. Accessed June 23, 2009.
6. Relkin NR, Szabo P, Adamiak B, et al.: 18-month study of intravenous immunoglobulin for treatment of mild Alzheimer disease. Neurobiol Aging 2008 Feb 20 (Epub ahead of print).
7. Wyeth: Elan and Wyeth Plan to Amend Bapineuzumab Phase 3 Protocols. Available at http://www.wyeth.com/news?nav=display&navTo=/wyeth_html/ home/news/pressreleases/2009/1238676245463.html. Accessed June 23, 2009.
8. Pfeifer M, Boncristiano S, Bondolfi L, et al.: Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002, 298:1379.
9. Siemers ER, Quinn JF, Kaye J, et al.: Effects of a gammasecretase inhibitor in a randomized study of patients with Alzheimer disease. Neurology 2006, 66:602-604.
10. Wilcock GK, Black SE, Hendrix SB, et al.: Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: A randomised phase II trial. Lancet Neurol 2008, 7:483-493.
11. Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan™ in Alzheimer's Disease: Flurizan Fails to Achieve Significance on Either Co-Primary Endpoint; Company Has Decided to Discontinue its Development of Flurizan. Available at http://www.myriad.com/news/release/1170283. Accessed June 23, 2009.
12. Wilcock GK, Balch AH, Amato DA, et al.: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month international multi-center phase 3 trial. Presented at the International Conference on Alzheimer's Disease. Chicago; July 26-31, 2008.
13. Arbel M, Solomon B: A novel immunotherapy for Alzheimer's disease: antibodies against the beta-secretase cleavage site of APP. Curr Alzheimer Res 2007, 4:437-445.
14. Terry RD: Tangles precede plaques but don't cause them. Neurobiol Aging 2004, 25:741-742; discussion 743-746.
15. Haroutunian V, Davies P, Vianna C, et al.: Tau protein abnormalities associated with the progression of Alzheimer disease type dementia. Neurobiol Aging 2007, 28:1-7.
16. Murayama S, Saito Y: Neuropathological diagnostic criteria for Alzheimer's disease. Neuropathology 2004, 24:254-260.
17. Sun X, Sato S, Murayama O, et al.: Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett 2002, 321:61-64.
18. Michaelis ML, Ansar S, Chen Y, et al.: {beta}-Amyloidinduced neurodegeneration and protection by structurally diverse microtubule-stabilizing agents. J Pharmacol Exp Ther 2005, 312:659-668.
19. Butler D, Bendiske J, Michaelis ML, et al.: Microtubule-stabilizing agent prevents protein accumulation-induced loss of synaptic markers. Eur J Pharmacol 2007, 562:20-27.
20. Wischik CM, Edwards PC, Lai RY, et al.: Selective inhibition of Alzheimer disease-like tau aggregation by phenothiazines. Proc Natl Acad Sci U S A 1996, 93:11213-11218.
21. Atamna H, Nguyen A, Schultz C, et al.: Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways. FASEB J 2008, 22:703-712.
22. Alzheimer Research Forum: Chicago: Out of the Blue - A Tau-Based Treatment for AD? Available at http://www.alzforum.org/new/detail.asp?id= 1892. Accessed June 23, 2009.
23. Aisen PS: The inflammatory hypothesis of AlzDeimer disease: dead or alive? Alzheimer Dis Assoc Disord 2008, 22:4-5.
24. Aisen PS, Davis KL, Berg JD, et al.: A randomized controlled trial of prednisone in Alzheimer's disease. Alzheimer's Disease Cooperative Study. Neurology 2000, 54:588-593.
25. Van Gool WA, Weinstein HC, Scheltens P, Walstra GJ: Effect of hydroxychloroquine on progression of dementia in early Alzheimer's disease: An 18-month randomised, double-blind, placebo-controlled study. Lancet 2001, 358:455-460.
26. Aisen PS, Schafer KA, Grundman M, et al.: Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: A randomized controlled trial. JAMA 2003, 289:2819-2826.
27. ReineN SA, Block GA, Morris JC, et al.: Rofecoxib: no effect on Alzheimer's disease in a 1-year, randomized, blinded, controlled study. Neurology 2004, 62:66-71.
28. Stampfer MJ, Malinow MR, Willett WC, et al.: A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992, 268:877-881.
29. Bostom AG, Silbershatz H, Rosenberg IH, et al.: Nonfasting plasma total homocysteine levels and all-cause and cardiovascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999, 159:1077-1080.
30. Bostom AG, Rosenberg IH, Silbershatz H, et al.: Nonfasting plasma total homocysteine levels and stroke incidence in elderly persons: The Framingham Study. Ann Intern Med 1999, 131:352-355.
31. Seshadri S, Beiser A, Selhub J, et al.: Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N Engl J Med 2002, 346:476-483.
32. Aisen PS, Schneider LS, Sano M, et al.: High-dose B vitamin supplementation and cognitive decline in Alzheimer disease: A randomized controlled trial. JAMA 2008, 300:1774-1783.
33. Viswanathan A, Raj S, Greenberg SM, et al.: Plasma Abeta, homocysteine, and cognition: The Vitamin Intervention for Stroke Prevention (VISP) trial. Neurology 2009, 72:268-272.
34. Fassbender K, Simons M, Bergmann C, et al.: Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo. Proc Natl Acad Sci U S A 2001, 98:5856-5861.
35. Zhou B, Teramukai S, Fukushima M: Prevention and treatment of dementia or Alzheimer's disease by statins: A meta-analysis. Dement Geriatr Cogn Disord 2007, 23:194-201.
36. Sjogren M, Gustafsson K, Syversen S, et al.: Treatment with simvastatin in patients with Alzheimer's disease lowers both alpha- and beta-cleaved amyloid precursor protein. Dement Geriatr Cogn Disord 2003, 16:25-30.
37. Carlsson CM, Gleason CE, Hess TM, et al.: Effects of simvastatin on cerebrospinal fluid biomarkers and cognition in middle-aged adults at risk for Alzheimer's disease. J Alzheimers Dis 2008, 13:187-197.
38. Sparks DL, Petanceska S, Sabbagh M, et al.: Cholesterol, copper and Abeta in controls, MCI, AD and the AD cholesterol-lowering treatment trial (ADCLT). Curr Alzheimer Res 2005, 2:527-539.
39. Sparks DL, Sabbagh MN, Connor DJ, et al.: Atorvastatin for the treatment of mild to moderate Alzheimer disease: Preliminary results. Arch Neurol 2005, 62:753-757.
40. Sparks DL, Connor DJ, Sabbagh MN, et al.: Circulating cholesterol levels, apolipoprotein E genotype and dementia severity influence the benefit of atorvastatin treatment in Alzheimer's disease: Results of the Alzheimer's Disease Cholesterol-Lowering Treatment (ADCLT) trial. Acta Neurol Scand Suppl 2006, 185:3-7.
41. Sano M: Multi-center, randomized, double-blind, placebocontrolled trial of simvastatin to slow the progression of Alzheimer's disease. Presented at the International Conference on Alzheimer's Disease. Chicago; July 26-31, 2008.
42. Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002, 360:7-22.
43. Shepherd J, Blauw GJ, Murphy MB, et al.: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): A randomised controlled trial. Lancet 2002, 360:1623-1630.
44. Henderson VW, Paganini-Hill A, Miller BL, et al.: Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial. Neurology 2000, 54:295-301.
45. Mulnard RA, Cotman CW, Kawas C, et al.: Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: A randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA 2000, 283:1007-1015.
46. Wang PN, Liao SQ, Liu RS, et al.: Effects of estrogen on cognition, mood, and cerebral blood flow in AD: A controlled study. Neurology 2000, 54:2061-2066.
47. Shumaker SA, Legault C, Rapp SR, et al.: Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: The Women's Health Initiative MAmory Study: a randomized controlled trial. JAMA 2003, 289:2651-2662.
48. Sasaki N, Toki S, Chowei H, et al.: Immunohistochemical distribution of the receptor for advanced glycation end products in neurons and astrocytes in Alzheimer's disease. Brain Res 2001, 888:256-262.
49. Ahen X, Walker DG, Schmidt AM, et al.: RAGE: a potential target for Abeta-mediated cellular perturbation in Alzheimer's disease. Curr Mol Med 2007, 7:735-742.
50. Lermontova NN, Lukoyanov NV, Serkova TP, et al.: Dimebon improves learning in animals with experimental Alzheimer's disease. Bull Exp Biol Med 2000, 129:544-546.
51. Grigorev VV, Dranyi OA, Bachurin SO: Comparative study of action mechanisms of dimebon and memantine on AMPA- and NMDA-subtypes glutamate receptors in rat cerebral neurons. Bull Exp Biol Med 2003, 136:474-477.
52. Lermontova NN, Redkozubov AE, Shevtsova EF, et al.: Dimebon and tacrine inhibit neurotoxic action of beta-amyloid in culture and block L-type Ca(2+) channels. Bull Exp Biol Med 2001, 132:1079-1083.
53. Bachurin SO, Shevtsova EP, Kireeva EG, et al.: Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 2003, 993:334-344; discussion 345-339.
54. Doody RS, Gavrilova SI, Sano M, et al.: Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomised, double-blind, placebocontrolled study. Lancet 2008, 372:207-215.
55. Russo O, Cachard-Chastel M, Riviere C, et al.: Design, synthesis, and biological evaluation of new 5-HT4 receptor agonists: Application as amyloid cascade modulators and potential therapeutic utility in Alzheimer's disease. J Med Chem 2009, 52:2214-2225.
56. Spencer JP, Brown JT, Richardson JC, et al.: Modulation of hippocampal excitability by 5-HT4 receptor agonists persists in a transgenic model of Alzheimer's disease. Neuroscience 2004, 129:49-54.
57. Alzheimer Research Forum: Drugs In Clinical Trials (PRX-03140). Available at http://www.alzforum.org/dis/tre/drc/detail.asp?id=113. Accessed June 23, 2009.
58. Thal LJ, Ferris SH, Kirby L, et al.: A randomized, double-blind, study of rofecoxib in patients with mild cognitive impairment. Neuropsychopharmacology 2005, 30:1204-1215.
59. Group AR, Lyketsos CG, Breitner JC, et al.: Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. Neurology 2007, 68:1800-1808.
60. Meinert CL, McCaffrey LD, Breitner JC: Alzheimer's Disease Anti-inflammatory Prevention Trial: Design, methods, and baseline results. Alzheimers Dement 2009, 5:93-104.
61. Breitner JC, Haneuse SJ, Walker R, et al.: Risk of dementia and AD with prior exposure to NSAIDs in an elderly community-based cohort. Neurology 2009, 72:1899-1905.
62. Shumaker SA, Legault C, Kuller L, et al.: Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2947-2958.
63. Craig MC, Maki PM, Murphy DG: The Women's Health Initiative Memory Study: Findings and implications for treatment. Lancet Neurol 2005, 4:190-194.
64. Rapp SR, Espeland MA, Shumaker SA, et al.: Effect of estrogen plus progestin on global cognitive function in postmenopausal women: The Women's Health Initiative Memory Study: A randomized controlled trial. JAMA 2003, 289:2663-2672.
65. Espeland MA, Rapp SR, Shumaker SA, et al.: Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study. JAMA 2004, 291:2959-2968.
66. Maki PM, Gast MJ, Vieweg AJ, et al.: Hormone therapy in menopausal women with cognitive complaints: A randomized, double-blind trial. Neurology 2007, 69:1322-1330.
67. DeKosky ST, Williamson JD, Fitzpatrick AL, et al.: Ginkgo biloba for prevention of dementia: A randomized controlled trial. JAMA 2008, 300:2253-2262.
68. Freund-Levi Y, Eriksdotter-Jonhagen M, Cederholm T, et al.: Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease:AOmegAD study: a randomized double-blind trial. Arch Neurol 2006, 63:1402-1408.
69. van de Rest O, Geleijnse JM, Kok FJ, et al.: Effect of fish oil on cognitive performance in older subjects: A randomized, controlled trial. Neurology 2008, 71:430-438.
70. Lautenschlager NT, Cox KL, Flicker L, et al.: Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease: A randomized trial. JAMA 2008, 300:1027-1037.
71. Willis SL, Tennstedt SL, Marsiske M, et al.: Long-term effects of cognitive training on everyday functional outcomes in older adults. JAMA 2006, 296:2805-2814.
72. Smith GE, Housen P, Yaffe K, et al.: A cognitive training program based on principles of brain plasticity: Results from the Improvement in Memory with Plasticity-based Adaptive Cognitive Training (IMPACT) study. J Am Geriatr Soc 2009, 57:594-603.